Cemiplimab
- Generic Name
- Cemiplimab
- Brand Names
- Libtayo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1801342-60-8
- Unique Ingredient Identifier
- 6QVL057INT
- Background
Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.
...
- Indication
Cemiplimab is indicated to treat:
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Metastatic cutaneous squamous cell carcinoma, Recurrent Cervical Cancer, Metastatic Basal cell carcinoma
- Associated Therapies
- First Line Chemotherapy
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 317
- Registration Number
- NCT05137054
- Locations
- 🇺🇸
Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 370
- Registration Number
- NCT05125016
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- OncoResponse, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT05094804
- Locations
- 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸NEXT Austin, Austin, Texas, United States
Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-12-11
- Target Recruit Count
- 13
- Registration Number
- NCT05064085
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 60
- Registration Number
- NCT04989946
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-12-17
- Target Recruit Count
- 32
- Registration Number
- NCT04988074
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 237
- Registration Number
- NCT04982224
- Locations
- 🇺🇸
University of California Irvine School of Medicine - Suite 400, Room 407, Orange, California, United States
🇺🇸University of Colorado Hospital Anshutz Outpatient Pavillion, Denver, Colorado, United States
🇺🇸Johns Hopkins Hospital - Clinical Study Location - Skip Viragh Outpatient Cancer Building, Baltimore, Maryland, United States
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-11-28
- Target Recruit Count
- 30
- Registration Number
- NCT04975152
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 77
- Registration Number
- NCT04916002
- Locations
- 🇺🇸
University of California, Los Angeles, California, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
- Conditions
- Interventions
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 46
- Registration Number
- NCT04913220
- Locations
- 🇫🇷
Investigational Site Number : 2500003, Bobigny, France
🇨🇱Investigational Site Number : 1520006, Antofagasta, Chile
🇦🇺Investigational Site Number : 0360001, Macquarie University, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.